Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1956 1
1957 1
1961 2
1962 1
1969 1
1970 1
1971 1
1972 2
1973 1
1974 1
1975 1
1976 1
1977 1
1978 2
1979 1
1981 1
1982 1
1983 1
1985 4
1986 4
1987 2
1988 2
1990 2
1991 1
1992 2
1993 2
1994 2
1995 2
1996 2
1997 2
1998 5
1999 11
2000 6
2001 5
2002 3
2003 6
2004 7
2005 12
2006 12
2007 11
2008 14
2009 20
2010 19
2011 21
2012 30
2013 21
2014 25
2015 35
2016 38
2017 21
2018 31
2019 22
2020 24
2021 27
2022 31
2023 25
2024 20
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

498 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Eating Disorders and Diabetes.
Winston AP. Winston AP. Curr Diab Rep. 2020 Jun 15;20(8):32. doi: 10.1007/s11892-020-01320-0. Curr Diab Rep. 2020. PMID: 32537669 Review.
Neuropharmacology.
Winston A, Manji H. Winston A, et al. Handb Clin Neurol. 2018;152:55-64. doi: 10.1016/B978-0-444-63849-6.00005-0. Handb Clin Neurol. 2018. PMID: 29604984 Review.
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, Molina JM, Guaraldi G, Winston A, Boesecke C, Cinque P, Bamford A, Calmy A, Marzolini C, Martínez E, Oprea C, Welch S, Koval A, Mendao L, Rockstroh JK; EACS Governing Board. Ambrosioni J, et al. Among authors: winston a. HIV Med. 2023 Nov;24(11):1126-1136. doi: 10.1111/hiv.13542. Epub 2023 Oct 18. HIV Med. 2023. PMID: 37849432
Cognitive impairment in people living with HIV: consensus recommendations for a new approach.
Nightingale S, Ances B, Cinque P, Dravid A, Dreyer AJ, Gisslén M, Joska JA, Kwasa J, Meyer AC, Mpongo N, Nakasujja N, Pebody R, Pozniak A, Price RW, Sandford C, Saylor D, Thomas KGF, Underwood J, Vera JH, Winston A. Nightingale S, et al. Among authors: winston a. Nat Rev Neurol. 2023 Jul;19(7):424-433. doi: 10.1038/s41582-023-00813-2. Epub 2023 Jun 13. Nat Rev Neurol. 2023. PMID: 37311873 Review.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Cognitive Impairment in a Clinical Setting.
Ferretti F, Mora-Peris B, Underwood J, Waldman A, Everitt A, Winston A. Ferretti F, et al. Among authors: winston a. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e10-e13. doi: 10.1097/QAI.0000000000001547. J Acquir Immune Defic Syndr. 2018. PMID: 28902706 Free article. No abstract available.
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.
Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm NM, McKay PF, Rampling T, Yim YTN, Milinkovic A, Kingsley C, Cole T, Fagerbrink S, Aban M, Tanaka M, Mehdipour S, Robbins A, Budd W, Faust SN, Hassanin H, Cosgrove CA, Winston A, Fidler S, Dunn DT, McCormack S, Shattock RJ; COVAC1 study Group. Pollock KM, et al. Among authors: winston a. EClinicalMedicine. 2022 Feb;44:101262. doi: 10.1016/j.eclinm.2021.101262. Epub 2022 Jan 14. EClinicalMedicine. 2022. PMID: 35043093 Free PMC article.
498 results